The key difference between menactra and menveo is that menactra is a meningococcal vaccine for Neisseria meningitidis that is approved for ages between 9 months to 55 years, while menveo is a meningococcal vaccine approved for ages between 2 months to 55 years.
Meningococcal vaccines are approved by US Food and Drug Administration (FDA) to prevent infection by Neisseria meningitidis bacterium. Different versions of these vaccines are effective against some or all of the serotypes of meningococcus, such as A, B, C, W-135, and Y. Moreover, these vaccines are between 85 and 100% effective against Neisseria meningitidis bacterium for at least two years. Menactra and menveo are two types of meningococcal vaccines which approved for different ages by the FDA, USA.
CONTENTS
1. Overview and Key Difference
2. What is Menactra
3. What is Menveo
4. Similarities – Menactra and Menveo
5. Menactra vs Menveo in Tabular Form
6. Summary – Menactra vs Menveo
What is Menactra?
Menactra is a meningococcal vaccine used for the prevention of infections by Neisseria meningitidis. This vaccine is approved for ages between 9 months to 55 years. Menactra is a conjugate meningococcal vaccine approved by the FDA, USA, in 2005. It is effective against Neisseria meningitidis serotypes such as A, B, C, and W. The world health organization usually recommends that countries with a moderate or high rate of Neisseria meningitidis infections should routinely vaccinate their population with this vaccine or any other appropriate vaccine. In countries with low risk, immunization is done only for high-risk groups. The effectiveness of this vaccine is around 59 to 82%
This vaccine usually works by exposing people to a small dose of bacteria or its protein. This causes the human body to develop immunity to meningococcal disease. Menactra is given as an injection into a muscle. A booster dose is needed if people have high risk. The booster dose is given after 4 years after the first dose. Furthermore, the side effects of menactra may include severe weakness, high fever, unusual behaviour, nausea, vomiting diarrhoea, changes in appetite, joint or muscle pain, headache, drowsiness, fussiness, and irritability.
What is Menveo?
Menveo is a meningococcal vaccine used for the prevention of infection by Neisseria meningitidis and is approved for ages between 2 months to 55 years. Menveo was first approved by FDA, USA, in 2010. It is also effective against Neisseria meningitidis serotypes such as A, B, C, and W-135. The effectiveness of this vaccine is around 80 to 85%.
Menveo vaccine is also given as an injection through the muscle. Furthermore, the side effects of menveo may include hives, dizziness, weakness, fast heartbeats, difficulty in breathing, swelling of the face, lips, tongue or throat, high fever, unusual behaviour, nausea, vomiting, redness, pain, swelling or hard lumps in the area the vaccine given, joint or muscle pain, headache, drowsiness, and irritability.
What are the Similarities Between Menactra and Menveo?
- Menactra and menveo are two types of meningococcal vaccines approved by the FDA for different ages.
- Both vaccines are conjugate vaccines.
- Both vaccines are effective against serotypes of meningococcus, such as A, B, C, and W-135.
- They work by exposing people to a small dose of bacteria or its protein.
- Both vaccines are given to children as well as adults.
- They may have side effects.
What is the Difference Between Menactra and Menveo?
Menactra is a meningococcal vaccine used for the prevention of infection by Neisseria meningitidis and is approved for ages between 9 months to 55 years, while menveo is a meningococcal vaccine used for the prevention of infection by Neisseria meningitidis and is approved for ages between 2 months to 55years. Thus, this is the key difference between menactra and menveo.
The below infographic presents the differences between menactra and menveo in tabular form for side-by-side comparison.
Summary – Menactra vs Menveo
Menactra and menveo are two types of meningococcal vaccines approved for different ages by the FDA, USA. Both these vaccines are conjugate vaccines and are effective against serotypes of meningococcus such as A, B, C, and W-135. Menactra is a meningococcal vaccine used for the prevention of infection by Neisseria meningitides. It is approved for ages between 9 months to 55 years. Menveo is a meningococcal vaccine used for the prevention of infection by Neisseria meningitidis and approved for ages between 2 months to 55 years. So, this is the key difference between menactra and menveo.
Reference:
1. “Menactra (Vaccine): Uses, Dosage & Side Effects.” Drugs.com.
2. “Menveo (Meningococcal [Groups A,C,Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine): Dosing and Administration.” GSK – For HealthCare Professionals.
Image Courtesy:
1. “General Photo: Vaccine” By Asian Development Bank (CC BY-NC 2.0) via Flickr